3.0TMRIPDFF和IP-OP对脂肪肝定量评估的价值

doi:10.13481/j.1671-587x.20200434

摘要/Abstract

摘要： 目的：探讨3.0T磁共振成像（MRI）质子密度脂肪分数（PDFF）和同反相位（IP-OP）定量评估肝脏脂肪含量的应用价值，为脂肪肝无创性定量分析提供参考依据。方法：本组研究对象包括轻度脂肪肝患者34例、中重度脂肪肝患者29例和非脂肪肝患者（对照组）20例，均经肝穿刺活检确诊。采用MRI-PDFF和MRI-IP-OP技术检测各组患者肝脏脂肪分数（HFF），采用Kruskal-Wallis检验进行多组间比较，采用Mann-Whitney检验进行组间两两比较，同时进行Bonferroni校正。采用受试者工作特征（ROC）曲线分析2种技术定量评估脂肪肝的诊断效能。结果：各组患者MRI-PDFF和MRI-IP-OP的HFF比较差异有统计学意义（P<0.01）。中重度脂肪肝组患者MRI-PDFF的HFF较对照组和轻度脂肪肝组明显升高（P<0.01），轻度脂肪肝组患者MRI-PDFF的HFF较对照组明显升高（P<0.01）。中重度脂肪肝组患者MRI-IP-OP的HFF较对照组和轻度脂肪肝组患者明显升高（P<0.01），轻度脂肪肝组患者MRI-IP-OP的HFF较对照组明显升高（P<0.05）。ROC曲线显示，诊断轻度脂肪肝（对照组vs轻度脂肪肝组+中重度脂肪肝组），MRI-PDFF和MRI-IP-OP的HFF曲线下面积（AUC）分别为0.931和0.874；诊断中重度脂肪肝（对照组+轻度脂肪肝组vs中重度脂肪肝组），MRI-PDFF和MRI-IP-OP的HFFAUC分别为0.928和0.913。结论：对于轻度脂肪肝和中重度脂肪肝，MRI-PDFF具有更高的诊断效能，是一种精确而可靠的无创性肝脏脂肪变性定量分析方法。

关键词: 磁共振成像, 脂肪肝, 质子密度脂肪分数, 同反相位

Abstract: Objective: To explore the application values of 3.0T magnetic resonance imaging(MRI) proton density fat-fraction(PDFF) and in-phase and opposed-phase(IP-OP) in the quantitative evaluation of liver fat content,and to provide the reference for non-invasive quantitative analysis of fatty liver. Methods: A total of 34 mild fatty liver patients, 29 moderate to severe fatty liver patients and 20 non-fatty liver patients (control group) were selected.All patients were diagnosed by liver biopsy. The hepatic fat fractions(HFF) of patients were detected by MRI-PDFF and MRI-IP-OP techniques. Kruskal-Wallis test was used to compare the differences in HFF between various groups. Mann-Whitney test and Bonferroni correction were used to compare the differences of HFF between two groups. The receiver operating characteristic(ROC) curve was drawn to analyze the diagnossis efficiency of each technique to evaluate the liver steatosis. Results: There were significant differences in HFF of MRI-PDFF and MRI-IP-OP of the patients between various groups(P<0.01).The HFF of MRI-PDFF of the patients in moderate and severe fatty liver group was higher than those in control group and mild fatty liver group(P<0.01), and the HFF of the patients in mild fatty liver group was higher than that in control group(P<0.01).The HFF of MRI-IP-OP the patients in moderate and severe fatty liver group was higher than those in control group and mild fatty liver group(P<0.01), and the HFF of the patients in mild fatty liver group was higher than that in control group (P<0.05).The ROC curve showed that the areas under curve(AUC) of MRI-PDFF and MRI-IP-OP in the diagnosis of mild fatty liver were 0.931 and 0.874, respectively, and the AUC of MRI-PDFF and MRI-IP-OP in the diagnosis of moderate and severe farry liver were 0.928 and 0.913, respectively. Conclusion: For the mild and moderate to severe fatty liver, MRI-PDFF has a more higher diagnosis efficiency,and it is a accurate, reliable,and non-invasive quantitative analysis method for liver steatosis.

Key words: magnetic resonance image, fatty liver, proton density fat-fraction, in-phase and opposed-phase

中图分类号:

R445.2

杨逸铭, 刘玉品, 周懂晶, 陈志远, 萧焕明, 池晓玲. 3.0TMRIPDFF和IP-OP对脂肪肝定量评估的价值[J]. 吉林大学学报(医学版), 2020, 46(04): 875-880.

YANG Yiming, LIU Yupin, ZHOU Dongjing, CHEN Zhiyuan, XIAO Huanming, CHI Xiaoling. Values of 3.0T MRI PDFF and IP-OP in quantificative evaluation on fatty liver[J]. Journal of Jilin University(Medicine Edition), 2020, 46(04): 875-880.

参考文献

[1] JEON S K, LEE J M, JPP I, et al. Prospective evaluation of hepatic gteatosis using ultrasound attenuation imaging in patients with chronic liver disease with magnetic resonance imaging proton density fat fraction as the reference standard[J]. Ultrasound Med Biol, 2019, 45(6):1407-1416.
[2] CUNHA G M, THAI T T, HAMILTON G, et al. Accuracy of common proton density fat fraction thresholds for magnitude- and complex-based chemical shift-encoded MRI for assessing hepatic steatosis in patients with obesity[J]. Abdom Radiol (NY), 2020, 45(3):661-671.
[3] FRIEDMAN S L, NEUSCHWANDER-TETRI B A, RINELLA M, et al. Mechanisms of NAFLD development and therapeutic strategies[J]. Nat Med, 2018, 24(7):908-922.
[4] KÜHN J P, MEFFERT P, HESKE C, et al. Prevalence of fatty liver disease and hepatic iron overload in a northeastern German population by using quantitative MR imaging[J]. Radiology, 2017, 284(3):706-716.
[5] IDILMAN I S, KESKIN O, CELIK A, et al. A comparison of liver fat content as determined by magnetic resonance imaging-proton density fat fraction and MRS versus liver histology in non-alcoholic fatty liver disease[J]. Acta Radiol, 2015, 57(3):271-278.
[6] TADA T, KUMADA T, TOYODA H, et al. Utility of attenuation coefficient measurement using an ultrasound-guided attenuation parameter for evaluation of hepatic steatosis:comparison with MRI-determined proton density fat fraction[J]. Am J Roentgenol, 2019, 212(2):332-341.
[7] CORRIAS G, KREBS S, ESKREIS-WINKLER S, et al. MRI liver fat quantification in an oncologic population:the added value of complex chemical shift-encoded MRI[J]. Clin Imaging, 2018, 52:193-199.
[8] TANG A, TAN J, SUN M, et al. Nonalcoholic fatty liver disease:MR imaging of liver proton density fat fraction to assess hepatic steatosis[J]. Radiology, 2013, 267(2):422-431.
[9] IDILMAN I S, ANIKTAR H, IDILMAN R, et al. Hepatic steatosis:quantification by proton density fat fraction with MR imaging versus liver biopsy[J]. Radiology, 2013, 267(3):767-775.
[10] YE J, WU Y, LI F, et al. Effect of orlistat on liver fat content in patients with nonalcoholic fatty liver disease with obesity:assessment using magnetic resonance imaging-derived proton density fat fraction[J]. Therapeut Adv Gastroenterol, 2019. DOI:10.1177/1756284819879047.
[11] LEE S J, KIM S U. Noninvasive monitoring of hepatic steatosis:controlled attenuation parameter and magnetic resonance imaging-proton density fat fraction in patients with nonalcoholic fatty liver disease[J]. Expert Rev Gastroenterol Hepatol, 2019, 13(6):523-530.
[12] MCHENRY S, SHARMA Y, TIRATH A, et al. Crohn's disease is associated with an increased prevalence of nonalcoholic fatty liver disease:a cross-sectional study using magnetic resonance proton density fat fraction mapping[J]. Clin Gastroenterol Hepatol, 2019, 17(13):2816-2818.
[13] GU J L, LIU S S, DU S X, et al. Diagnostic value of MRI-PDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease:a meta-analysis[J]. Eur Radiol, 2019, 29(7):3564-3573.
[14] GUO Z, BLAKE G M, LI K, et al. Liver fat content measurement with quantitative CT validated against MRI proton density fat fraction:a prospective study of 400 healthy volunteers[J]. Radiology, 2020, 294(1):89-97.
[15] FERRAIOLI G, MAIOCCHI L, RACITI M V, et al. Detection of liver steatosis with a novel ultrasound-based technique:a pilot study using MRI-derived proton density fat fraction as the gold standard[J]. Clin Transl Gastroenterol, 2019, 10(10):e00081.
[16] LEITÃO H S, PAULINO C, RODRIGUES D, et al. MR fat fraction mapping[J]. Acad Radiol, 2013, 20(8):957-961.
[17] IDILMAN I S, TUZUN A, SAVAS B, et al. Quantification of liver, pancreas, kidney, and vertebral body MRI-PDFF in non-alcoholic fatty liver disease[J].Abdom Imaging, 2015, 40(6):1512-1519.
[18] DI MARTINO M, PACIFICO L, BEZZI M, et al. Comparison of magnetic resonance spectroscopy, proton density fat fraction and histological analysis in the quantification of liver steatosis in children and adolescents[J]. World J Gastroenterol, 2016, 22(39):8812-8819.
[19] NOUREDDIN M, LAM J, PETERSON M R, et al. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials[J]. Hepatology, 2013, 58(6):1930-1940.
[20] TANG A, DESAI A, HAMILTON G, et al. Accuracy of MR imaging-estimated proton density fat fraction for classification of dichotomized histologic steatosis grades in nonalcoholic fatty liver disease[J]. Radiology, 2015, 274(2):416-425.
[21] 周懂晶,黄丽霞,刘玉品,等. 3.0 T磁共振IDEAL-IQ技术定量评估脂肪肝的价值[J]. 中华生物医学工程杂志. 2017, 23(1):55-58.
[22] COLGAN T J, VAN PAY A J, SHARMA S D, et al. Diurnal variation of proton density fat fraction in the liver using quantitative chemical shift encoded MRI[J]. J Magn Reson Imaging, 2020, 51(2):407-414.
[23] 洪佳,施漪雯,吴晓宁,等.影像学诊断技术在非酒精性脂肪性肝病中的应用价值[J].临床肝胆病杂志,2018,34(12):2698-2701.